Henrijette Richter is a Managing Partner at Sofinnova Partners and an active member of the Capital Funds team, the firm’s flagship fund dedicated to early-stage biotechs and medtechs.

What does it take to develop traction and get a term sheet from your lead investors? Strong science is merely one factor but often not enough. This meeting is a unique opportunity to discuss with one of Europe’s most experienced life science investors what really matters when you pitch for your venture financing and crossover rounds.

Henrijette Richter a Managing Partner at Sofinnova Partners and an active member of the Capital Funds team, the firm’s flagship fund dedicated to early-stage biotechs and medtechs.

She joined Sofinnova in 2014, and her investments and board involvements include Mozart Therapeutics, Muna Therapeutics, Nitrase Therapeutics, NodThera, Twentyeight-Seven Therapeutics, Asceneuron, Delinia (sold to Celgene), and iOmx Therapeutics.

Prior to Sofinnova, Henrijette was part of the team that founded Novo Seeds in 2007, and as an Investment Director, she was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead), and Lysogene (LYS, Euronext Paris).

Henrijette holds a combined Ph.D. and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts.